Trazodone Dosing for Agitation
Start trazodone at 25 mg per day and titrate up to a maximum of 200-400 mg per day in divided doses for managing agitation, particularly in patients with dementia or severe psychomotor agitation. 1
Initial Dosing Strategy
The evidence-based approach for trazodone in agitation management follows a clear titration protocol:
- Starting dose: 25 mg per day 1
- Target range: 200-400 mg per day in divided doses 1
- Titration: Increase gradually based on clinical response and tolerability
This dosing is specifically recommended for trazodone's use as a mood-stabilizing (antiagitation) drug rather than as an antidepressant, where it serves as a useful alternative to antipsychotic agents for control of severe agitated, repetitive, and combative behaviors 1.
Clinical Context and Evidence Quality
The primary guideline evidence 1 consistently categorizes trazodone under "mood-stabilizing (antiagitation) drugs" with recommended uses for "control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness." This classification is distinct from its antidepressant indication, where FDA labeling recommends starting at 150 mg/day 2.
Important distinction: The FDA-approved dosing for depression (150 mg/day initial, up to 400-600 mg/day) 2 differs from the agitation-specific dosing in clinical practice guidelines, which emphasizes starting lower at 25 mg/day for behavioral management 1.
Supporting Research Evidence
A double-blind trial comparing trazodone to haloperidol for agitation in dementia patients used doses of 50-250 mg/day, demonstrating equal efficacy to haloperidol with fewer adverse effects 3. The study found that trazodone preferentially improved repetitive, verbally aggressive, and oppositional behaviors.
Recent evidence from 2025 examining IV trazodone in major depressive disorder with mixed features showed effectiveness in reducing psychomotor agitation, with correlation analyses indicating that therapy duration (rather than dosage alone) significantly influenced outcomes 4.
Critical Safety Considerations
Cardiac precaution: Use trazodone with caution in patients with premature ventricular contractions 1.
Formulation matters: Recent geriatric emergency department guidelines 5 found that parenteral formulations of antipsychotics or anxiolytics significantly increase adverse events (OR 7.63-10.17) compared to oral administration. While this study didn't specifically examine trazodone, the principle of preferring oral formulations applies.
Avoid in certain populations: A 2020 VA/DoD guideline 6 advised against trazodone for chronic insomnia due to low-quality efficacy evidence and concerning adverse effect profile, though this was in the context of insomnia rather than acute agitation.
Practical Titration Algorithm
- Start: 25 mg once daily (typically at bedtime given sedating properties)
- Assess response: After 3-7 days
- Titrate: Increase by 25-50 mg increments every 3-7 days as tolerated
- Target: 200-400 mg/day in divided doses for full antiagitation effect
- Monitor: Watch for excessive sedation, orthostasis, and cardiac symptoms
Common Pitfalls to Avoid
- Don't confuse depression dosing with agitation dosing: The 150 mg starting dose for depression 2 is too high for initial agitation management
- Don't combine with multiple sedating agents: Particularly avoid combining with benzodiazepines in older adults, as this increases adverse events 5
- Don't use as monotherapy for severe acute agitation: In emergency settings with severe undifferentiated agitation, trazodone's slower onset makes it less suitable than agents like haloperidol or olanzapine 7
- Don't overlook cardiac history: Screen for arrhythmias and PVCs before initiating 1
The evidence consistently supports starting low (25 mg/day) and going slow with trazodone for agitation, with a therapeutic ceiling around 200-400 mg/day for behavioral symptoms—substantially different from its antidepressant dosing paradigm.